Search

Your search keyword '"Merad, Miriam"' showing total 1,556 results

Search Constraints

Start Over You searched for: Author "Merad, Miriam" Remove constraint Author: "Merad, Miriam"
1,556 results on '"Merad, Miriam"'

Search Results

1. Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.

3. The commitment of the human cell atlas to humanity

4. Circulating myeloid-derived MMP8 in stress susceptibility and depression

5. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis

6. Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative.

8. MacroH2A restricts inflammatory gene expression in melanoma cancer-associated fibroblasts by coordinating chromatin looping

9. Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study

12. Circulating proteins to predict COVID-19 severity

13. Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity

14. Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma

15. Embracing cancer complexity: Hallmarks of systemic disease

16. Ovarian cancer-derived IL-4 promotes immunotherapy resistance

17. TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer

18. Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma

20. Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae

21. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward.

22. Monocytes re-enter the bone marrow during fasting and alter the host response to infection

23. Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR

24. Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy

25. A methylation clock model of mild SARS‐CoV‐2 infection provides insight into immune dysregulation

26. The Human Cell Atlas White Paper

27. Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORγt+ Regulatory T Cells and Exacerbate Colitis in Mice

29. Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

30. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity

32. A translational genomics approach identifies IL10RB as the top candidate gene target for COVID-19 susceptibility

34. Correction: The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

35. The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

36. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

39. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.

40. Understanding the tumor immune microenvironment (TIME) for effective therapy

41. The Human Cell Atlas.

42. Accelerating diabetic wound healing by ROS-scavenging lipid nanoparticle–mRNA formulation

43. Supplementary Figure S17 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

44. Data from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

45. Supplementary Table S2 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

46. 16. Circulating Myeloid-Derived MMP8 in Stress Susceptibility and Depression

47. A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

48. Single cell view of tumor microenvironment gradients in pleural mesothelioma

49. Abstract B075: Spatial genomics identifies cancer cell cytokines regulating ovarian cancer immunity

50. Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience

Catalog

Books, media, physical & digital resources